4,508
Views
7
CrossRef citations to date
0
Altmetric
Rheumatology

Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan

, , , ORCID Icon, &
Pages 777-787 | Received 14 Aug 2018, Accepted 01 Apr 2019, Published online: 15 May 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sajith Kumar & Bhavani Shankara Bagepally. (2023) Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-14.
Read now

Articles from other publishers (6)

Ahmad Gholami, Jassem Azizpoor, Elham Aflaki, Mehdi Rezaee & Khosro Keshavarz. (2021) Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept. BioMed Research International 2021, pages 1-12.
Crossref
Karina Rossi Bonfiglioli, Licia Maria Henrique da Mota, Ana Cristina de Medeiros Ribeiro, Adriana Maria Kakehasi, Ieda Maria Magalhães Laurindo, Rina Dalva Neubarth Giorgi, Angela Luzia Branco Pinto Duarte, Ana Paula Monteiro Gomides Reis, Mariana Peixoto Guimarães Ubirajara e Silva de Souza, Claiton Viegas Brenol, Geraldo da Rocha Castelar Pinheiro, Cleandro Pires de Albuquerque, Charlles Heldan de Moura Castro, Gustavo Luiz Behrens Pinto, Jose Fernando Verztman, Luciana Feitosa Muniz, Manoel Barros Bertolo, Maria Raquel da Costa Pinto, Paulo Louzada Júnior, Vitor Alves Cruz, Ivanio Alves Pereira, Max Vitor Carioca de Freitas, Bóris Afonso Cruz, Eduardo Paiva, Odirlei Monticielo, José Roberto Provenza & Ricardo Machado Xavier. (2021) Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis. Advances in Rheumatology 61:1.
Crossref
Chongqing Tan, Sini Li, Lidan Yi, Xiaohui Zeng, Liubao Peng, Shuxia Qin, Liting Wang & Xiaomin Wan. (2021) Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population. Advances in Therapy 38:5, pages 2571-2585.
Crossref
Lei Tian, Xiaomo Xiong, Qiang Guo, Yixi Chen, Luying Wang, Peng Dong & Aixia Ma. (2020) Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China. PharmacoEconomics 38:12, pages 1345-1358.
Crossref
F. Navarro, J. M. Martinez-Sesmero, A. Balsa, C. Peral, M. Montoro, M. Valderrama, S. Gómez, F. de Andrés-Nogales, M. A. Casado & Itziar Oyagüez. (2020) Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clinical Rheumatology 39:10, pages 2919-2930.
Crossref
Michael Mahler, Laura Martinez-Prat, Jeffrey A. Sparks & Kevin D. Deane. (2020) Precision medicine in the care of rheumatoid arthritis: Focus on prediction and prevention of future clinically-apparent disease. Autoimmunity Reviews 19:5, pages 102506.
Crossref